Related Experiment Videos
[Granulo-monocyte growth factors. Their value in pneumonologic oncologic practice].
J Trédaniel1, P Brice, A Creange
1Service de Pneumologie, Hôpital Saint-Louis, Paris.
Revue Des Maladies Respiratoires
|January 1, 1991
Summary
Granulo-monocytic growth factors, including GM-CSF and G-CSF, show promise in cancer therapy by potentially increasing drug doses and reducing neutropenia. Further research is needed to confirm their safety and efficacy, especially regarding tumor growth stimulation.
Area of Science:
- Hematology and Oncology
- Molecular Biology
Context:
- Growth factors are crucial for regulating cell production.
- Colony-stimulating factors (CSFs), specifically GM-CSF and G-CSF, are glycoproteins involved in hematopoiesis.
Purpose:
- To explore the therapeutic potential of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in cancer treatment.
- To assess the role of these factors in managing chemotherapy-induced side effects and enabling dose intensification.
Summary:
- Genetically engineered GM-CSF and G-CSF are in therapeutic trials, primarily for solid tumors.
- These factors may allow for increased chemotherapy doses and reduced neutropenia duration, thereby lowering infection risk.
- Potential applications include adjuvant therapy in small cell lung cancer and supporting intensified chemotherapy regimens.
Impact:
- CSFs could significantly alter the management of cytotoxic drug therapy, particularly in solid tumors.
- Clinical experience is limited, mainly to hematological applications.
- Long-term safety, including the absence of tumor growth stimulation, requires further investigation before widespread adoption.